Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

6 de novembro de 2014 atualizado por: GlaxoSmithKline

A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer

This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.

Visão geral do estudo

Status

Rescindido

Condições

Intervenção / Tratamento

Descrição detalhada

Study 109609 is a single-arm, non-randomized, single-stage Phase II study of pazopanib in subjects with Stage IIIB or IV non-small cell lung cancer who have progressed after one or two prior regimens of systemic therapy. The study will be conducted at a limited number of institutions in the US. A total of 40 evaluable subjects will be enrolled and treated. Pazopanib will be given at a dose of 800mg (as determined by previous Phase I studies) orally once per day. Subjects may continue to receive study drug for up to two years unless they experience disease progression or withdraw from treatment for other reasons, or unless the Sponsor terminates the study. A rollover study may be available to those subjects who are exhibiting clinical benefit (stable disease or better). Evaluable subjects will be assessed for response as the primary endpoint.

Tipo de estudo

Intervencional

Inscrição (Real)

14

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85258
        • GSK Investigational Site
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33916
        • GSK Investigational Site
      • Orlando, Florida, Estados Unidos, 32806
        • GSK Investigational Site
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70809
        • GSK Investigational Site
    • Minnesota
      • Duluth, Minnesota, Estados Unidos, 55805
        • GSK Investigational Site
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43219
        • GSK Investigational Site
    • Oklahoma
      • Tulsa, Oklahoma, Estados Unidos, 74136
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19106
        • GSK Investigational Site
      • Sayre, Pennsylvania, Estados Unidos, 18840
        • GSK Investigational Site
    • Texas
      • Corpus Christi, Texas, Estados Unidos, 78463-3069
        • GSK Investigational Site
    • Virginia
      • Newport News, Virginia, Estados Unidos, 23601
        • GSK Investigational Site
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • GSK Investigational Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Signed consent
  • Histologically- or cytologically confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer.
  • Failed no more than two prior chemotherapy regimens for Stage IIIB or IV non-small cell lung cancer, including a platinum-containing regimen.
  • Brain metastases permitted if subject has been treated with surgery and/or radiation therapy more than 4 weeks prior to date of first dose and is stable for at least one week off steroids.
  • 18 years of age or older.
  • Eastern Cooperative Oncology Group performance status of at least 2.
  • Measurable disease according to RECIST.
  • Adequate organ system function.
  • Females may be eligible to enroll if they are of non-childbearing potential (surgically sterile or post-menopausal)or are using appropriate contraception methods.

Exclusion Criteria:

  • Prior malignancy - unless disease-free for at least 3 years, or have had completely resected non-melanomatous skin cancer or successfully treated in situ carcinoma.
  • History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for subjects with previously-treated CNS metastases, who are asymptomatic, and have had no requirement for steroids or anti-seizure medication for one week prior to first dose of study drug.
  • Clinically significant gastrointestinal abnormalities.
  • Presence of uncontrolled infection.
  • Corrected QT interval greater than 480 msec.
  • History of significant cardiovascular condition(s).
  • Poorly controlled hypertension (systolic blood pressure of 140mmHG or greater or diastolic blood pressure of 90mmHg or greater).
  • History of cerebrovascular accident, pulmonary embolism, or insufficiently treated deep venous thrombosis within the past 6 months prior to first dose of study drug.
  • Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
  • Active bleeding or diathesis.
  • Hemoptysis in excess of 2.5mL within 8 weeks of first dose of study drug.
  • Serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedures.
  • Use of prohibited medications as defined in protocol.
  • Use of an investigational agent, including an investigational anti-cancer agent within 28 days, or 5 half-lives, whichever is longer, prior to first dose of study drug.
  • Prior use of any investigational or licensed anti-angiogenic agent, including thalidomide and agents that target platelet-derived growth factor. Prior treatment with bevacizumab or epidermal growth factor receptor tyrosine kinase inhibitors

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Pazopanib Open-label
Single-arm, non-randomised, single-stage pazopanib monotherapy.
Medicamento: Pazopanib (GW786034)
Pazopanib monotherapy

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants Who Achieved Either a Confirmed Complete Response or Partial Response Per RECIST Criteria
Prazo: Baseline through End of Study (up to 2 years)
The best overall response using Response Evaluation Criteria In Solid Tumors (RESIST) was measured. Complete response is defined as the disappearance of all known lesion(s), confirmed at 4 weeks, and partial response is defined as at least a 30% decrease in the sum of the longest diameters of target lesions taken as a reference to baseline sum of the longest diameters, confirmed at 4 weeks. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants Who Had a Complete or Partial Response, or Stable Disease
Prazo: Baseline through End of Study (up to 2 years)
Disease control was measured. Stable disease (SD) is defined as neither partial response (at least a 30% decrease in the sum of the longest diameters of target lesions taken as a reference to baseline sum of the longest diameters, confirmed at 4 weeks) nor progressive disease (PD; a 20% increase in the sum of the longest diameters of target lesions, taken as a reference the smallest sum of the longest diameter recorded since the treatment started or the appearance of one or more new lesions. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)
Progression-Free Survival
Prazo: Baseline through End of Study (up to 2 years)
Progression-free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause, whichever occurs first. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)
Overall Survival
Prazo: Baseline through End of Study (up to 2 years)
Overall survival is defined as the time from the start of treatment until death due to any cause. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)
Levels of Circulating Biomarkers in Plasma
Prazo: Baseline through End of Study (up to 2 years)
Biomarkers are proteins that respond in a unique way to treatment with the study drug; however, levels of proteins were not collected for this measurement. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)
Characterization of Participant Populations by Identification of Intra-tumoral Biomarkers
Prazo: Baseline through End of Study (up to 2 years)
Biomarkers are proteins that respond in a unique way to treatment with the study drug; however, levels of proteins were not collected for this measurement. No formal efficacy analyses were performed due to early termination of the study.
Baseline through End of Study (up to 2 years)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

GlaxoSmithKline

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de fevereiro de 2008

Conclusão Primária (Real)

1 de abril de 2009

Conclusão do estudo (Real)

1 de abril de 2009

Datas de inscrição no estudo

Enviado pela primeira vez

23 de outubro de 2007

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de outubro de 2007

Primeira postagem (Estimativa)

25 de outubro de 2007

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

19 de novembro de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2014

Última verificação

1 de novembro de 2014

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 109609

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Câncer de Pulmão de Células Não Pequenas

Ensaios clínicos em Pazopanib (GW786034)

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Chile

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever